FDA Reconsideration Leads to Approval of Takeda Drug for Rare Esophagus Disorder

MedCity News February 12, 2024
Frank Vinluan

FDA approval of Takeda Pharmaceutical drug Eohilia introduces a new therapeutic option for patients with eosinophilic esophagitis, inflammation of the esophagus that causes swallowing difficulty. It will compete against Dupixent, a Sanofi and Regeneron Pharmaceuticals drug already approved for this disorder.

A Takeda Pharmaceutical drug for an allergic condition affecting the esophagus is now approved, a regulatory decision that comes a little more than two years after the FDA initially turned down the pharma giant’s application. The regulatory decision gives Takeda the opportunity to offer patients a drug with different dosing than a blockbuster product that Sanofi markets for the condition.

The FDA approval announced Monday covers the treatment of pediatric and adult patients who have eosinophilic esophagitis, a condition...

Today's Sponsors

Today's Sponsor